INmune Crashes After Missing Cognitive Target in Phase II Alzheimer’s Trial
Digging into a prespecified analysis for the mid-stage study, INmune Bio identified some clinical and biological benefits of its TNF inhibitor in patients with early Alzheimer’s disease who have at least two biomarkers of inflammation.
INmune Crashes After Missing Cognitive Target in Phase II Alzheimer’s Trial Read More »
